Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Marzia Varettoni, Emilia Cappello, Emanuela Boveri, Virginia Valeria Ferretti, Silvia Zibellini, Gianmarco Favrin, Chiara Varraso, Marco Lucioni, Cristina Picone, Giulia Vittoria Facchetti, Giovanni O. Palladini, Marco Paulli, Luca Arcaini

Blood (2024) 144 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2024-207850

Published: 2024

Journal Articles

Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity

Elisabetta Molteni, Elisa Bono, Anna Gallì, Chiara Elena, Jacqueline Ferrari, Nicolas Fiorelli, Sara Pozzi, Virginia Valeria Ferretti, Martina Sarchi, Ettore Rizzo, Virginia Camilotto, Emanuela Boveri, Mario Cazzola, Luca Malcovati

Blood (2023) 142 (7): 643–657.

https://doi.org/10.1182/blood.2022019304

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 4001–4004.

https://doi.org/10.1182/blood-2022-166050

Published: 2022

Journal Articles

Relationship between clone metrics and clinical outcome in clonal cytopenia

Blood (2021) 138 (11): 965–976.

https://doi.org/10.1182/blood.2021011323

Published: 2021

Includes: Supplemental data

Journal Articles

Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Irene Defrancesco, Silvia Zibellini, Emanuela Boveri, Marco Frigeni, Virginia Valeria Ferretti, Ettore Rizzo, Francesca Capuano, Arturo Bonometti, Chiara Candido, Sara Rattotti, Elena Flospergher, Fabio Bergamini, Caterina Zerbi, Marco Paulli, Marzia Varettoni, Luca Arcaini

Blood (2019) 134 (Supplement_1): 1502.

https://doi.org/10.1182/blood-2019-130233

Published: 2019

Journal Articles

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Blood (2018) 132 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2018-99-118123

Published: 2018

Journal Articles

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Blood (2017) 130 (Supplement 1): 2959.

https://doi.org/10.1182/blood.V130.Suppl_1.2959.2959

Published: 2017

Journal Articles

Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization

ELISA Bono, MD, Donal McLornan, Erica Travaglino, Shreyans Gandhi, MBBS,MDMNAMS, Anna Gallì, Alesia Abigael Khan, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Emanuela Boveri, Kavita Raj, Chiara Elena, Robin M. Ireland, FRCP, Antonio Bianchessi, Jie Jiang, Gabriele Todisco, Luca Malcovati, MD, Judith Marsh, MD, Mario Cazzola, MD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 588.

https://doi.org/10.1182/blood.V130.Suppl_1.588.588

Published: 2017

Journal Articles

Lymphoplasmacytic Lymphoma Not Associated with an IgM Monoclonal Paraprotein Has Distinctive Clinical and Biological Features and a Similar Outcome As Compared with Waldenstrom's Macroglobulinemia: Multicentric Study of the Rete Ematologica Lombarda

Blood (2017) 130 (Supplement 1): 4045.

https://doi.org/10.1182/blood.V130.Suppl_1.4045.4045

Published: 2017

Journal Articles

Clinical significance of somatic mutation in unexplained blood cytopenia

Blood (2017) 129 (25): 3371–3378.

https://doi.org/10.1182/blood-2017-01-763425

Published: 2017

Includes: Supplemental data

Journal Articles

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Blood (2015) 126 (2): 233–241.

https://doi.org/10.1182/blood-2015-03-633537

Published: 2015

Includes: Supplemental data

Journal Articles

Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin

Daniela Pietra, PhD, Elisa Rumi, MD, Chiara Milanesi, BS, Christian A Di Buduo, PhD, Marta Bellini, MD, Ilaria Carola Casetti, MD, Chiara Cavalloni, MD, Emanuela Sant'Antonio, Vittorio Abbonante, PhD, Maria C Renna, BS, Virginia Ferretti, PhD, Emanuela Boveri, MD, Alessandra Balduini, MD, Cristiana Pascutto, PhD, Mario Cazzola, MD

Blood (2014) 124 (21): 3215.

https://doi.org/10.1182/blood.V124.21.3215.3215

Published: 2014

Journal Articles

Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts

Blood (2014) 124 (21): 825.

https://doi.org/10.1182/blood.V124.21.825.825

Published: 2014

Journal Articles

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Blood (2014) 124 (9): 1513–1521.

https://doi.org/10.1182/blood-2014-03-560227

Published: 2014

Includes: Supplemental data

Journal Articles

Clinical effect of driver mutations of JAK2 , CALR , or MPL in primary myelofibrosis

Blood (2014) 124 (7): 1062–1069.

https://doi.org/10.1182/blood-2014-05-578435

Published: 2014

Journal Articles

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic, Ilaria C. Casetti, Marta Bellini, Nicole C. C. Them, Chiara Cavalloni, Virginia V. Ferretti, Chiara Milanesi, Tiina Berg, Emanuela Sant’Antonio, Emanuela Boveri, Cristiana Pascutto, Cesare Astori, Robert Kralovics, Mario Cazzola

Blood (2014) 123 (15): 2416–2419.

https://doi.org/10.1182/blood-2014-01-550434

Published: 2014

Includes: Supplemental data

Journal Articles

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

Blood (2014) 123 (12): 1836–1849.

https://doi.org/10.1182/blood-2013-04-497271

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Blood (2014) 123 (10): 1544–1551.

https://doi.org/10.1182/blood-2013-11-539098

Published: 2014

Includes: Supplemental data

Journal Articles

JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum

Elisa Rumi, MD, Daniela Pietra, PhD, Chiara Elena, MD, Ilaria Casetti, MD, Emanuela Sant 'Antonio, MD, Cesare Astori, MD, Chiara Milanesi, PhD, Marta Bellini, MD, Emanuela Boveri, MD, Virginia Ferretti, DR, Cristiana Pascutto, PhD, Mario Cazzola, MD

Blood (2013) 122 (21): 1592.

https://doi.org/10.1182/blood.V122.21.1592.1592

Published: 2013

Journal Articles

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

Marzia Varettoni, Silvia Zibellini, Luca Arcaini, Emanuela Boveri, Sara Rattotti, Cristiana Pascutto, Silvia Mangiacavalli, Manuel Gotti, Lara Pochintesta, Marco Paulli, Mario Cazzola

Blood (2013) 122 (13): 2284–2285.

https://doi.org/10.1182/blood-2013-07-513366

Published: 2013

NARROW

Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?

Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity

Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Relationship between clone metrics and clinical outcome in clonal cytopenia

Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization

Lymphoplasmacytic Lymphoma Not Associated with an IgM Monoclonal Paraprotein Has Distinctive Clinical and Biological Features and a Similar Outcome As Compared with Waldenstrom's Macroglobulinemia: Multicentric Study of the Rete Ematologica Lombarda

Clinical significance of somatic mutation in unexplained blood cytopenia

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin

Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia

Clinical effect of driver mutations of JAK2 , CALR , or MPL in primary myelofibrosis

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only